ロード中...
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
IMPORTANCE: In a comparative clinical study with progression-free survival (PFS) or overall survival (OS) as the end point, the hazard ratio (HR) is routinely used to design the study and to estimate the treatment effect at the end of the study. The clinical interpretation of the HR may not be strai...
保存先:
| 出版年: | JAMA Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Medical Association
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5824272/ https://ncbi.nlm.nih.gov/pubmed/28975263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2797 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|